Buscar
Mostrando ítems 1-10 de 22
Estudio Farmacoeconómico de Pazopanib y Sunitinib en el tratamiento de Cáncer Renal
(Medicina-Quimica, 2014)
Economic evaluation of sunitinib versus pazopanib and best supportive care for the treatment of metastatic renal cell carcinoma in Chile: cost-effectiveness analysis and a mixed treatment comparison
(Facultad de Medicina y Ciencia, 2019)
Background: Sunitinib and Pazopanib are two metastatic renal cell carcinoma (MRCC) treatment alternatives, however the health system in Chile does not consider coverage for any. The cost-effectiveness versus relevant ...
Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study
(2018)
Background: The tyrosine kinase inhibitor pazopanib is used for treatment of sarcoma. Recent studies have suggested that the use of pazopanib may lead to the development of pneumothorax, an unexpected adverse effect in ...